The prevalence and severity of acute and chronic graft-versus-host disease in patients with histologic BOOP and in control subjects
Factor . | BOOP patients, N = 48 Value . | Control subjects, N = 155 Value . | P . |
|---|---|---|---|
| Acute GVHD | |||
| Prevalence (%)* | 39 (81) | 87 (56) | .002 |
| Mean overall grade (SD) | 2.04 (1.09) | 1.54 (1.29) | .02 |
| Mean organ grade—skin (SD) | 2.27 (1.16) | 1.43 (1.37) | <.001 |
| Mean organ grade—liver (SD) | 0.81 (1.14) | 0.72 (1.22) | .65 |
| Mean organ grade—gut (SD) | 0.75 (0.98) | 0.66 (1.05) | .62 |
| Chronic GVHD (%)† | |||
| Prevalence chronic GVHD‡ | 37 (87) | 85 (64) | .02 |
| Severity at onset‡ | .02 | ||
| Clinical extensive | 37 (85) | 78 (59) | |
| Clinical limited | 1 (2) | 7 (5) | |
| Skin involvement§ | 28 (76) | 83 (68) | .72 |
| Liver involvement§ | 10 (27) | 41 (34) | .97 |
| Gut involvement§ | 13 (36) | 20 (16) | .04 |
| Oral involvement§ | 27 (73) | 70 (57) | .26 |
| Eye involvement§ | 16 (44) | 32 (26) | .17 |
| Chronic GVHD classification (%)∥ | .001 | ||
| De novo | 5 (13) | 27 (23) | |
| Quiescent | 15 (39) | 39 (33) | |
| Progressive | 12 (32) | 9 (8) | |
| Not applicable¶ | 6 (16) | 43 (36) |
Factor . | BOOP patients, N = 48 Value . | Control subjects, N = 155 Value . | P . |
|---|---|---|---|
| Acute GVHD | |||
| Prevalence (%)* | 39 (81) | 87 (56) | .002 |
| Mean overall grade (SD) | 2.04 (1.09) | 1.54 (1.29) | .02 |
| Mean organ grade—skin (SD) | 2.27 (1.16) | 1.43 (1.37) | <.001 |
| Mean organ grade—liver (SD) | 0.81 (1.14) | 0.72 (1.22) | .65 |
| Mean organ grade—gut (SD) | 0.75 (0.98) | 0.66 (1.05) | .62 |
| Chronic GVHD (%)† | |||
| Prevalence chronic GVHD‡ | 37 (87) | 85 (64) | .02 |
| Severity at onset‡ | .02 | ||
| Clinical extensive | 37 (85) | 78 (59) | |
| Clinical limited | 1 (2) | 7 (5) | |
| Skin involvement§ | 28 (76) | 83 (68) | .72 |
| Liver involvement§ | 10 (27) | 41 (34) | .97 |
| Gut involvement§ | 13 (36) | 20 (16) | .04 |
| Oral involvement§ | 27 (73) | 70 (57) | .26 |
| Eye involvement§ | 16 (44) | 32 (26) | .17 |
| Chronic GVHD classification (%)∥ | .001 | ||
| De novo | 5 (13) | 27 (23) | |
| Quiescent | 15 (39) | 39 (33) | |
| Progressive | 12 (32) | 9 (8) | |
| Not applicable¶ | 6 (16) | 43 (36) |
Data not available for 1 case patient and 6 control subjects.
Calculations reflect patients at risk for chronic GVHD.
Data not available for 6 case patients and 28 control subjects.
Data not available for 12 case patients and 39 control subjects.
Data not available for 11 case patients and 43 control subjects.
Not applicable indicates no clinical extensive chronic GVHD.